Search...
/
The Fly Cast
Press play to listen
Smarter market moves start here
Competitive Advantages
Proprietary Allogeneic CAR T Platform: Development of CD305 (CoVigil™), a universal, off-the-shelf CAR T-cell therapy platform, has the potential to overcome manufacturing and logistical challenges associated with autologous CAR T therapies.
Diverse Cell Therapy Pipeline: Their portfolio extends beyond CAR T to include natural killer (NK) cell therapies, an allogeneic stem cell platform, and an adenovirus platform, diversifying their therapeutic approaches and market potential.
Advanced CAR T-Cell Modulation Technologies: Technologies like SNAP-CAR™ and GEAR-T™ aim to provide precise control over CAR T-cell activity, potentially enhancing safety, reducing toxicity, and improving efficacy by allowing for titratable responses.
Risks
Clinical Trial Failure Risk: Development of drug candidates may not be successful in clinical trials, or may not meet primary endpoints, leading to delays or discontinuation.
Regulatory Approval Uncertainty Risk: Despite successful clinical results, Coeptis may not receive the necessary regulatory approvals from agencies like the FDA or EMA, which could prevent commercialization.
Significant Capital Requirements Risk: Coeptis will require substantial additional financing to complete its drug development programs and operations, and such funding may not be available on favorable terms or at all.
Today
7:09 AM
Over a week ago
Jun 9, 6:00 PM
Jun 4, 7:08 AM
May 27, 7:13 AM
May 19, 8:09 AM
No more stories